Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.19EUR
15 Jan 2019
Change (% chg)

-- (--)
Prev Close
€74.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,528,082
52-wk High
€80.44
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 31.12 34.38
EPS (TTM): 3.70 -- --
ROI: 5.69 15.55 14.96
ROE: 8.50 16.93 16.53

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

07 Jan 2019

UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

07 Jan 2019

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

PARIS Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

07 Jan 2019

CORRECTED-UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal

PARIS, Jan 7 Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

07 Jan 2019

Drugmakers Sanofi, Regeneron restructure immuno-oncology deal

PARIS, Jan 7 Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million.

07 Jan 2019

Sanofi to invest 80 mln euros in German biotech group BioNTech

FRANKFURT, Jan 4 French drugmaker Sanofi will invest 80 million euros ($90.9 million) in BioNTech and expand its collaboration with the German biotech group, BioNTech said on Friday.

04 Jan 2019

Sanofi's pediatric hexavalent vaccine approved by U.S. FDA

PARIS The U.S. Food and Drug Administration approved Sanofi's new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

26 Dec 2018

Sanofi's paediatric hexavalent vaccine approved by U.S. FDA

PARIS, Dec 26 The U.S. Food and Drug Administration approved Sanofi's new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

26 Dec 2018

Mylan says Sanofi loses Lantus insulin patent claims

U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

13 Dec 2018

UPDATE 2-Mylan says Sanofi loses Lantus insulin patent claims

Dec 13 U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

13 Dec 2018

Earnings vs. Estimates